2D and 3D-QSAR analysis of pyrazole-thiazolinone derivatives as EGFR kinase inhibitors by CoMFA and CoMSIA

Curr Comput Aided Drug Des. 2015;11(4):292-303. doi: 10.2174/1573409912666151106120058.

Abstract

Two and Three-dimensional quantitative structure-activity relationship (2D, 3D-QSAR) study was performed for some pyrazole-thiazolinone derivatives as EGFR kinase inhibitors using the CoMFA, CoMSIA and GA-MLR methods. The utilized data set was split into training and test set based on hierarchical clustering technique. From the five CoMSIA descriptors, electrostatic field presented the highest correlation with the activity. The statistical parameters for the CoMFA (r(2)=0.862, q(2)=0.644) and CoMSIA (r(2)=0.851, q(2)=0.740) were obtained for the training set with the common substructure-based alignment. The obtained parameters indicated the superiority of the CoMSIA model over the CoMFA model. A test set consisted of seven compounds was used to evaluate the proposed models. The results of contour maps which were presented by each method lead to some insights for increasing the inhibition activity of compounds. The 2D-QSAR model was built based on three descriptors selected by genetic algorithm and showed high predictive ability (R(2) train= 0.843, Q(2) LOO=0.787). Molecular docking study was also performed to understand the type interactions presented in binding site of the receptor and ligand. The developed models in parallel with molecular docking can be employed to design and derive novel compounds with the potent EGFR inhibitory activity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Computer-Aided Design
  • Drug Design
  • ErbB Receptors / antagonists & inhibitors*
  • ErbB Receptors / metabolism
  • Humans
  • Molecular Docking Simulation
  • Protein Kinase Inhibitors / chemistry*
  • Protein Kinase Inhibitors / pharmacology*
  • Pyrazoles / chemistry*
  • Pyrazoles / pharmacology*
  • Quantitative Structure-Activity Relationship
  • Static Electricity
  • Thiazoles / chemistry*
  • Thiazoles / pharmacology*

Substances

  • Protein Kinase Inhibitors
  • Pyrazoles
  • Thiazoles
  • EGFR protein, human
  • ErbB Receptors